4C Medical's Novel Mitral Regurgitation Therapy to be Presented at TCT 2017 Shark Tank Innovation Competition
BROOKLYN PARK, Minnesota, Oct. 24, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) will be highlighted in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) meeting held October 29-November 2, 2017 in Denver, CO.
4C Medical is developing the first MR treatment that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates known issues associated with current transcatheter mitral valve replacement (TMVR) technologies which rely on placement and fixation in the native mitral annulus and left ventricle.
Philippe Généreux, MD, will present "A Novel Trans-catheter Mitral Valve Replacement Technology (4C)" at 8:30 am Tuesday, October 31 in the Colorado Convention Center Four Seasons Ballroom 4. Dr. Généreux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).
"We're excited for Dr. Généreux to present on our technology at TCT, the premier educational meeting for interventional cardiology," said Robert Thatcher, CEO of 4C Medical. "Participating in the Innovation Competition validates the uniqueness of our device, which has potential to provide treatment options for a broad patient population suffering from moderate or severe MR."
About 4C Medical Technologies, Inc.
4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. The company's implant is the first MR treatment with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle.
Media Contacts
Robert Thatcher
Chief Executive Officer
(612) 600-8951
rthatcher@4CMed.com
Jim Flaherty
Chief Financial Officer
(612) 599-0650
jflaherty@4CMed.com
Logo - https://mma.prnewswire.com/media/587874/4C_Logo_RGB.jpg
Share this article